ETFdb Logo
ETFdb Logo
ETFdb Logo
ETFdb Logo
  • Channels
    • Active ETF
    • Alternatives
    • Beyond Basic Beta
    • China Insights
    • Climate Insights
    • Commodities
    • Core Strategies
    • Crypto
    • Disruptive Technology
    • Dividend
    • Dual Impact
    • Emerging Markets
    • Energy Infrastructure
    • Entrepreneur ETF
    • Equity ETF
    • ESG
    • ETF Building Blocks
    • ETF Education
    • ETF Strategist
    • Fixed Income
    • Future ETFs
    • Gold & Silver Investing
    • Innovative ETFs
    • Institutional Income Strategies
    • Leveraged & Inverse
    • Managed Futures
    • Modern Alpha
    • Multi-Asset
    • Multi-Factor
    • Nasdaq Investment Intelligence
    • Portfolio Strategies
    • Retirement Income
    • Smart Beta
    • Thematic Investing
    • Volatility Resource
  • Database
  • Tools
    • ETF Screener
    • ETF Country Exposure Tool
    • ETF Sector Tracker Tool
    • ETF Database Categories
    • Head-To-Head ETF Comparison Tool
    • ETF Stock Exposure Tool
    • ETF Issuer Fund Flows
    • Indexes
    • Mutual Fund To ETF Converter
    • ETF Data for Journalists
    • ETF Nerds
  • Research
    • First Bitcoin ETF
    • ETF Education
    • Equity Investing
    • Dividend ETFs
    • Leveraged ETFs
    • Inverse ETFs
    • Top ETF Sectors
    • Top ETF Issuers
    • Top ETF Industries
  • Webcasts
    • ETFs Future-Forward 2021: An iShares Investing Symposium
    • Three Themes for 2021: An iShares & MSCI Investing Symposium
  • Themes
    • AI ETFs
    • Blockchain ETFs
    • See all Thematic Investing ETF themes
    • ESG Investing
    • Marijuana ETFs
  • Videos & Podcasts
    • ETF 360 Video Series
    • ETF Trends on Videos
    • ETF Trends on Podcasts
    • ETF Prime Podcast
  • PRO
    • Pro Content
    • Pro Tools
    • Advanced
    • FAQ
    • Pricing
    • Free Sign Up
    • Login
  1. China Insights Channel
  2. ‘KMED’ Could Gain from Approval of Chinese Vaccine
China Insights Channel
Share

'KMED' Could Gain from Approval of Chinese Vaccine

Karrie GordonJun 04, 2021
2021-06-04

On Tuesday, the World Health Organization approved a Covid-19 vaccine produced by Sinovac Biotech for emergency use, the second vaccine created in China to be approved according to Reuters.

That could be good news for the KraneShares Emerging Market Healthcare Index ETF (KMED), which holds several Chinese pharmaceutical stocks.

Although Sinovac isn’t one of KMED’s holdings, the positive vaccine news could ripple throughout the healthcare sector, in a rising tide that lifts all boats.

New Vaccine Is 100% Effective Against Severe COVID

The Sinovac vaccine will be approved for all adults ages 18 and older, after a safety, efficacy, and manufacturing review by the WHO technical board.

The efficacy rate given by the WHO for the vaccine is 51% for preventing symptomatic disease, and 100% for preventing severe COVID-19 and hospitalization.

This particular vaccine will be branded CoronaVac and is the eighth Covid-19 vaccine to be approved by the WHO. It joins the only other Chinese vaccine to have been approved, one that was produced by Sinopharm, a state-backed pharmaceutical company.

A third Chinese vaccine produced by CanSino Biologics has provided the WHO with clinical trial data but is not yet scheduled for review.


Content continues below advertisement

'KMED' Capitalizes on Vaccine Developments

The KraneShares Emerging Market Healthcare Index ETF (KMED) provides exposure to small-, mid- and large-cap companies across the emerging markets that are involved with pharmaceutical manufacturing, biotechnology, hospital and healthcare management, and other sub-industries.

The healthcare industry in emerging markets tends to exhibit low correlation to the U.S. healthcare industry, notes KraneShares.

KMED has a 97.83% allocation to the healthcare sector and a 1.59% allocation to consumer staples.

The fund holds more than 150 stocks. Currently, its top holdings include Celltrion Inc, at 4.42%; Samsung Biologics, at 4.14%; and Shenzhen Mindray, at 4.01%.

Over the past 12 months, KMED is up 40.16%.

For more news, information, and strategy, visit the China Insights Channel.

Loading Articles...
Help & Info
  • Contact Us
  • About Us
  • Mission Statement
  • Press
Tools
  • ETF Screener
  • ETF Analyzer
  • Mutual Fund to ETF Converter
  • Head-To-Head ETF Comparison
  • ETF Country Exposure Tool
  • ETF Stock Exposure Tool
  • ETF Performance Visualizer
  • ETF Database Model Portfolios
  • ETF Database Realtime Ratings
  • ETF Database Pro
More Tools
  • ETF Launch Center
  • Financial Advisor & RIA Center
  • ETF Database RSS Feed
Explore ETFs
  • ETF News
  • ETF Picks of the Month
  • ETF Category Reports
  • Premium Articles
  • Alphabetical Listing of ETFs
  • Best ETFs
  • Browse ETFs by ETF Database Category
  • Browse ETFs by Index
  • Browse ETFs by Issuer
  • Compare ETFs
Legal
  • Terms of Use and Privacy Policy
  • © ETF Flows LLC
Follow ETF Database
Follow ETF Database

Advertisement

Is Your Portfolio Positioned With Enough Global Exposure?

Equity ETF Channel

Retirement Portfolio Redux: Is the 60%-40% Portfolio Dead?

Debbie CarlsonOct 22, 2020
2020-10-22

With the 10-year U.S. Treasury yield hovering below 1% and Federal Reserve Chairman Jerome Powell...

Equity ETF Channel

Portfolio Diversification Isn't Dead, It Was Just Sleeping

Debbie CarlsonOct 15, 2020
2020-10-15

Investors could be forgiven to think there was no reason to invest outside of the U.S. for the...

}
X